Stevens Meredith, Chief Operations Officer, has demonstrated a consistent pattern of selling activity in Kenvue Inc. (KVUE) shares, with no recorded purchases across 25 transactions totaling $457,544.77 in gross proceeds. The sales, executed between February 2024 and March 2026, include multiple high-value dispositions, such as a $149,236.29 transaction on February 8, 2024, followed by a $133,363.02 sale on February 13, 2026. Smaller but repeated sales occurred throughout the period, including a $31,214.48 disposition on March 10, 2026, and a $30,605.25 transaction on March 5, 2026. The filings indicate no open-market purchases ("M" code transactions) and only derivative dispositions ("F" code), suggesting the sales may involve stock option exercises or awards.
Meredith’s trading activity is exclusively tied to KVUE, the consumer health spinoff from Johnson & Johnson, with no diversification across other securities. The absence of buying activity and the repeated monetization of holdings—particularly concentrated in early 2024 and early 2026—reflect a sustained divestment strategy rather than periodic rebalancing. While the transactions do not indicate recent activity (the latest recorded sale was March 10, 2026), the two-year pattern underscores a clear directional bias toward reducing exposure to Kenvue equity. The lack of accompanying purchases distinguishes this from a hedging or dollar-cost averaging approach, presenting a straightforward sell-side trend.
AI-assisted summary